CHESTER SPRINGS, PA — NorthStar Medical Radioisotopes, LLC and Curadh MTR Inc. have announced a strategic long-term partnership to develop and produce pioneering radiopharmaceuticals aimed at diagnosing and treating solid tumor cancers.
Under the partnership, NorthStar will play a critical role in supporting the development of select Curadh radiopharmaceutical targets. This includes preparing and distributing patient doses of no-carrier-added Actinium-225 (n.c.a. Ac-225) for Curadh’s ongoing clinical studies. Upon approval, NorthStar may also manufacture and supply radiopharmaceuticals for commercial use.
The agreement further provides Curadh with access to NorthStar’s integrated radiopharmaceutical development and manufacturing organization. This access is expected to facilitate the development and commercialization of future radiopharmaceutical diagnostic and therapeutic agents.
Frank Scholz, Ph.D., CEO of NorthStar Medical Radioisotopes, expressed his optimism about the collaboration. He emphasized that NorthStar’s advanced technology and manufacturing expertise would help propel Curadh’s innovative radiopharmaceutical candidates, potentially benefiting cancer patients.
NorthStar is set to become one of the first commercial-scale producers of n.c.a. Ac-225. The company will utilize its advanced, environmentally preferable electron accelerator technology that currently supports the routine production of the therapeutic radioisotope copper-67 (Cu-67).
Scholz mentioned that NorthStar’s unique combination of radiopharmaceutical and manufacturing expertise allows the company to offer a powerful ‘end-to-end’ support package to its development collaborators. The company’s 52,000 square foot Contract Development and Manufacturing Organization (CDMO) facility is on schedule, with expectations of full operation by January 2025, pending necessary licensure and regulatory approvals.
Dr. Alison Armor, MD, FRCR, FRCP, CEO and founder of Curadh, highlighted the company’s focus on advancing new Medical Isotope Therapy (MTR) treatments for patients with primary and metastatic solid tumors. By partnering with NorthStar, a proven leader in nuclear medicine innovation and production, Armor believes they can ensure timely and efficient progression of their programs towards the clinic and offer patients broader access to potentially life-saving therapies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.